🕒 Friday 19 September 2025 Fri, 19 Sept 2025

Wellnex Life Limited has expanded its financing with a new A$2.5 million loan facility, enhancing its financial flexibility to support ongoing business growth and settle long-term obligations.

Island Pharmaceuticals has won a crucial FDA Type C meeting to discuss fast-tracking its antiviral Galidesivir for Marburg virus treatment, with written feedback expected by November.

Altitude Minerals has successfully raised $2.5 million to advance exploration at its promising silver and gold projects in Nevada and copper-gold targets in New South Wales, aiming to sustain momentum through 2026.

Swift Networks secures a landmark Master Services Agreement with Opal HealthCare to deploy its innovative Swift TV platform across multiple aged care communities, marking a significant step in aged care technology integration.

NoviqTech has launched beta versions of its pioneering quantum AI products, QI Provenance and QI AI, marking a significant step toward commercialising hybrid quantum-classical computing solutions. The company also announced plans for a powerful CUDA-Q enhanced platform promising up to tenfold acceleration in complex computing tasks.

Lunnon Metals has formalized an Ore Purchase Agreement with Gold Fields subsidiary St Ives Gold Mining, setting the stage for development of the high-grade Lady Herial gold deposit. The agreement outlines a 70, 30 free cash flow split and awaits shareholder and regulatory approvals.

InVert Graphite has appointed Andrew Lawson as Managing Director following his initial CEO tenure, signaling confidence in his leadership as the company advances its critical minerals projects.

Noronex Limited has kicked off a significant 7,000m reverse circulation drilling campaign at its Powerline Copper Project in Namibia, aiming to unlock new copper-silver deposits along the Kalahari Copper Belt. Funded by South32 under an earn-in agreement, this program targets promising domal structures identified by aeromagnetic surveys.

Platinum Asset Management confirms the Independent Expert's valuation of its proposed merger with L1 Capital remains unchanged after reviewing updated financials, with the Board unanimously recommending shareholder approval.

CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.

VHM Limited has obtained crucial federal environmental approval for its Goschen Rare Earths and Mineral Sands Project, clearing a major regulatory hurdle and setting the stage for development in 2026.

Atlas Arteria has announced a 20.0 cents per stapled security distribution for the first half of 2025, with payments scheduled for early October. The distribution reflects the company’s ongoing commitment to delivering steady returns from its international toll road assets.

Atlas Arteria has announced an ordinary dividend of AUD 0.20 per security for the six months ending June 2025, payable in early October. The dividend is fully unfranked, reflecting the company’s international income streams.

Kula Gold has intersected visible gold in quartz reefs during its maiden diamond drilling at the historic Mt Palmer Gold Project, with assay results eagerly awaited. This marks a promising step in the company’s efforts to unlock new high-grade gold resources in a historically rich region.

Equinox Resources has agreed to sell its Alturas Antimony Project in British Columbia to Maxus Mining, freeing up capital and focus for its core iron ore ambitions in Western Australia.

Perseus Mining has secured presidential approval to develop the CMA underground project at Yaouré, marking a pivotal expansion in Côte d’Ivoire’s gold mining sector. The project promises to extend mine life to 2035 with production ramping up by early 2027.

Summerset Group Holdings Limited has confirmed an ordinary dividend of NZD 0.113 per security for the half-year ending December 2025, alongside key updates to its Dividend Reinvestment Plan pricing and Australian dollar exchange rate.